Tables
- Table 1– Retrospective evaluation of the safety and tolerability of linezolid in 39 extensively drug-resistant tuberculosis cases
Adverse event Subgroup analysis LNZ ≤600 mg LNZ >600 mg p-value Total adverse events presumably due to linezolid 22/34 (64.7) 14/20 (70.0) 8/14 (57.1) 0.49 Major adverse events 21/28 (75.0) 16/20 (80.0) 5/8 (62.5) 0.37 Anaemia 9/29 (31.0) 5/21 (23.8) 4/8 (50.0) 0.21 Leukopenia 4/29 (13.8) 1/21 (4.8) 3/8 (37.5) 0.05 Thrombocytopenia 5/29 (17.2) 2/21 (9.5) 3/8 (37.5) 0.11 Peripheral neuropathy 16/29 (55.2) 11/21 (52.4) 5/8 (62.5) 0.70 Optic neuritis 5/25 (20.0) 2/17 (11.8) 3/8 (37.5) 0.28 Gastro-intestinal disorders 5/28 (17.9) 2/21 (9.5) 3/7 (42.9) 0.08 Exposure to linezolid days 315 (178–540) 270 (93–720) 330 (270–490) 0.64 Data are presented as n/n (%) or median (interquartile range), unless otherwise stated. LNZ: linezolid daily dose.
Vol 42 Issue 1
Table of Contents
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence
